Bartlesville Falcons

BIND Therapeutics reports income of $2.

BIND Therapeutics reports income of $2.1 million for fourth quarter 2013 BIND Therapeutics, Inc. , a clinical-stage nanomedicine platform organization developing targeted and programmable therapeutics called AccurinsTM, reported financial outcomes for the fourth one fourth and year-ended December 31 today, 2013 same formula . ‘2013 was a transformative season for BIND as we produced significant progress towards offering improved treatment plans for patients with cancers,’ stated Scott Minick, BIND's CEO and President. ‘We initiated two Stage 2 studies with this lead product applicant, BIND-014, in both metastatic castrate resistant prostate tumor and non-little cell lung tumor.